Articles Tagged With:
-
Big Sugar’s Smoking Gun
Though the influence of industry funding on research outcomes has long been a subject of concern for IRBs, it is unusual to find a “smoking gun” strongly linking an undisclosed funding source to biased research outcomes.
-
Historical Exposé on Sugar Industry Funding Research has Relevant Lessons for Current IRBs
A recently published study linking secret funding by the sugar industry to bias in research studies published in the 1960s is less a historical curiosity than a clear warning to IRBs to remain vigilant about conflicts of interest.
-
Highlights from Final Rule on Clinical Trial Results Submissions
The NIH published the final rule, “Clinical Trials Registration and Results Information Submission,” on Sept. 21, 2016, with an effective date of Jan. 18, 2017.
-
New NIH/FDA Rules Will Bring Greater Transparency to Clinical Trials
The new rules published this fall by the NIH and FDA about reporting clinical trial results will expand transparency in research and give the world more knowledge about the effectiveness of investigational and new drugs and devices, FDA and NIH officials say.
-
Ticagrelor vs. Aspirin: Post-TIA and Stroke
The first 90 days after a transient ischemic attack or ischemic stroke is a high-risk period for recurrence of cardiovascular thrombotic events. Even with aspirin treatment, recurrences occur in as many as 10-15% of patients. -
Heart Failure with Recovered Ejection Fraction: A Distinct Phenotype
SYNOPSIS: Patients suffering from systolic heart failure who subsequently improve their ejection fraction experience a more favorable clinical course compared to those presenting with persistently reduced ejection fraction or heart failure with preserved ejection fraction.
-
Noninvasive Ventilation Delivered Via Helmet May Decrease Intubation Rates
SYNOPSIS: In this single-center, randomized, clinical trial, among patients suffering from acute respiratory distress syndrome, the use of helmet noninvasive ventilation was associated with a reduction in intubation rates, ICU length of stay, and hospital and 90-day mortality.
-
Influence of Sacubitril/Valsartan on 30-day Readmission After Heart Failure
SYNOPSIS: Compared with enalapril, treatment with sacubitril/valsartan is more effective in reducing 30-day readmissions for any cause following discharge from congestive heart failure hospitalization.
-
Growing Threat of Pyelonephritis Caused by Antibiotic-resistant Escherichia coli
SYNOPSIS: In patients with acute pyelonephritis due Escherichia coli presenting to one of 10 emergency departments, the prevalence of fluoroquinolone resistance ranged from 6.3% to 19.9%, and the prevalence of extended-spectrum beta-lactamase production was 2.6% to 12.2%. Of those patients with resistant organisms, more than 50% received inactive empiric antibiotics.
-
Safely Centralized Telemetry Off-site in a Multi-hospital System
SYNOPSIS: The hospitals in this study outsourced their cardiac telemetry to an off-site central monitoring center without an increase in adverse events.